Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Janus Kinase 2 (JAK2) binds and is inhibited by several smal...
| Class:Id | Summation:9686366 |
|---|---|
| _displayName | Janus Kinase 2 (JAK2) binds and is inhibited by several smal... |
| _timestamp | 2020-04-30 09:18:10 |
| created | [InstanceEdit:9686364] Jassal, Bijay, 2020-04-30 |
| literatureReference | [LiteratureReference:9685059] Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [LiteratureReference:9684958] The use of Janus kinase inhibitors in the time of SARS-CoV-2 |
| text | Janus Kinase 2 (JAK2) binds and is inhibited by several small molecule drugs (Clark et al. 2014, Fridman et al. 2010, Hanan et al. 2012). The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases such as baricitinib, tofacitinib and ruxolitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020). |
| (summation) | [Reaction:9678561] IFNGR1:JAK1:INFGR2:JAK2 binds JAK1,2 inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Janus Kinase 2 (JAK2) binds and is inhibited by several smal... (9686366)
